CoChat

EU-Wi d e Cross-Section a l Obser v at i o n al Study of Lipid-Modifying Therapy Use in Se c ondary and Pr i mary Care: the DA VINCI study

Open access
Ray, Kausik K, Molemans, Bart, Schoonen, W Marieke, Giovas, Periklis, Bray, Sarah, Kiru, Gaia, Murphy, Jennifer, Banach, Maciej, De Servi, Stefano, Gaita, Dan, Gouni-Berthold, Ioanna, Hovingh, G Kees, Jozwiak, Jacek J, Jukema, J Wouter, Kiss, Robert Gabor, Kownator, Serge, Iversen, Helle K, Maher, Vincent, Masana, Luis, Parkhomenko, Alexander, Peeters, André, Clifford, Piers, Raslova, Katarina, Siostrzonek, Peter, Romeo, Stefano, Tousoulis, Dimitrios, Vlachopoulos, Charalambos, Vrablik, Michal, Catapano, Alberico L, Poulter, Neil R, the DA VINCI study · 2021 · European Journal of Preventive Cardiology

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Aims: To provide contemporary data on the implementation of European guideline recommendations for lipid-lowering therapies (LLTs) across different settings and populations and how this impacts low-density lipoprotein cholesterol (LDL-C) goal achievement. Methods and results: An 18 country, cross-sectional, observational study of patients prescribed LLT for primary or secondary prevention in primary or secondary care across Europe. Between June 2017 and November 2018, data were collected at a single visit, including LLT in the preceding 12 months and most recent LDL-C. Primary outcome was the achievement of risk-based 2016 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) LDL-C goal while receiving stabilized LLT; 2019 goal achievement was also assessed. Overall, 5888 patients (3000 primary and 2888 secondary prevention patients) were enrolled; 54% [95% confidence interval (CI) 52–56] achieved their risk-based 2016 goal and 33% (95% CI 32–35) achieved their risk-based 2019 goal. High-intensity statin monotherapy was used in 20% and 38% of very high-risk primary and secondary prevention patients, respectively. Corresponding 2016 goal attainment was 22% and 45% (17% and 22% for 2019 goals) for very high-risk primary and secondary prevention patients, respectively. Use of moderate–high-intensity statins in combination with ezetimibe (9%), or any LLT with PCSK9 inhibitors (1%), was low; corresponding 2016 and 2019 goal attainment was 53% and 20% (ezetimibe combination), and 67% and 58% (PCSK9i combination). Conclusion: Gaps between clinical guidelines and clinical practice for lipid management across Europe persist, which will be exacerbated by the 2019 guidelines. Even with optimized statins, greater utilization of non-statin LLT is likely needed to reduce these gaps for patients at highest risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjpc/zwaa047

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Estimated 10-year cardiovascular risk at low-density lipoprotein cholesterol measurement in primary prevention group a ( A ) and estimated 10-year risk of fatal and non-fatal cardiovascular events at low-density lipoprotein cholesterol measurement in established atherosclerotic cardiovascular disease group b ( B ). a Data shown are for all patients considered primary prevention at low-density lipoprotein cholesterol measurement ( n = 3142); of these, 2073 were on stabilized lipid-lowering therapy at low-density lipoprotein cholesterol measurement and had data available to calculate systematic coronary risk evaluation and glomerular filtration rate risk. b Data shown are for all patients considered having established atherosclerotic cardiovascular disease at low-density lipoprotein cholesterol measurement ( n = 2659); of these, 2039 were on stabilized lipid-lowering therapy at low-density lipoprotein cholesterol measurement. CV, cardiovascular; REACH, Reduction of Atherothrombosis for Continued Health; SCORE, systematic coronary risk evaluation.
Figure 1 Estimated 10-year cardiovascular risk at low-density lipoprotein cholesterol measurement in primary prevention group a ( A ) and estimated 10-year risk of fatal and non-fatal cardiovascular events at low-density lipoprotein cholesterol measurement in established atherosclerotic cardiovascular disease group b ( B ). a Data shown are for all patients considered primary prevention at low-density lipoprotein cholesterol measurement ( n = 3142); of these, 2073 were on stabilized lipid-lowering therapy at low-density lipoprotein cholesterol measurement and had data available to calculate systematic coronary risk evaluation and glomerular filtration rate risk. b Data shown are for all patients considered having established atherosclerotic cardiovascular disease at low-density lipoprotein cholesterol measurement ( n = 2659); of these, 2039 were on stabilized lipid-lowering therapy at low-density lipoprotein cholesterol measurement. CV, cardiovascular; REACH, Reduction of Atherothrombosis for Continued Health; SCORE, systematic coronary risk evaluation.CC-BY-NC · From the PDF
Figure 2 European Society of Cardiology/European Atherosclerosis Society 2016 and 2019 risk-based low-density lipoprotein cholesterol goal attainment among patients stabilized on lipid-lowering regimens summarized by level of risk and statin regimen. (A) The overall group summarized by level of risk and statin regimen ( B ) The Primary prevention group summarized by level of risk and statin regimen. ( C ) The established atherosclerotic cardiovascular disease group b summarized by level of risk and statin regimen. a Goal attainment for low risk is the same for 2016 and 2019 (<3.0 mmol/L) so only one bar is displayed. b Individuals with established atherosclerotic cardiovascular disease are, by definition, very high cardiovascular risk. N is the number of patients in the category with non-missing low-density lipoprotein cholesterol goal data. Patients enrolled as secondary prevention whose first atherosclerotic cardiovascular disease event occurred after the date low-density lipoprotein cholesterol levels were stabilized are included in the primary prevention group. Among patients enrolled as secondary prevention, 142 had their first cardiovascular event recorded after their most recent low-density lipoprotein cholesterol measurement, hence they were analysed as primary prevention patients for outcomes assessed at low-density lipoprotein cholesterol measurement, such as goal attainment. For outcomes assessed at enrolment, these 142 patients were analysed as secondary prevention. Definitions of lipid-lowering therapy categories are described in Supplementary material online, Table S2 . LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor.
Figure 2 European Society of Cardiology/European Atherosclerosis Society 2016 and 2019 risk-based low-density lipoprotein cholesterol goal attainment among patients stabilized on lipid-lowering regimens summarized by level of risk and statin regimen. (A) The overall group summarized by level of risk and statin regimen ( B ) The Primary prevention group summarized by level of risk and statin regimen. ( C ) The established atherosclerotic cardiovascular disease group b summarized by level of risk and statin regimen. a Goal attainment for low risk is the same for 2016 and 2019 (<3.0 mmol/L) so only one bar is displayed. b Individuals with established atherosclerotic cardiovascular disease are, by definition, very high cardiovascular risk. N is the number of patients in the category with non-missing low-density lipoprotein cholesterol goal data. Patients enrolled as secondary prevention whose first atherosclerotic cardiovascular disease event occurred after the date low-density lipoprotein cholesterol levels were stabilized are included in the primary prevention group. Among patients enrolled as secondary prevention, 142 had their first cardiovascular event recorded after their most recent low-density lipoprotein cholesterol measurement, hence they were analysed as primary prevention patients for outcomes assessed at low-density lipoprotein cholesterol measurement, such as goal attainment. For outcomes assessed at enrolment, these 142 patients were analysed as secondary prevention. Definitions of lipid-lowering therapy categories are described in Supplementary material online, Table S2 . LDL-C, low-density lipoprotein cholesterol; LLT, lipid-lowering therapy; PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitor.CC-BY-NC · From the PDF
Image 3
CC-BY-NC · From the PDF
Figure 2 Continued
Figure 2 ContinuedCC-BY-NC · From the PDF
Figure 3 Mean low-density lipoprotein cholesterol levels in patients with stabilized lipid-lowering therapy. n , the number of patients in the category on stabilized lipid-lowering therapy and with non-missing low-density lipoprotein cholesterol goal data. a Primary prevention: at low-density lipoprotein cholesterol measurement, 142 patients enrolled as secondary prevention, whose first atherosclerotic cardiovascular disease event occurred after the date low-density lipoprotein cholesterol levels were stabilized, are included in the primary prevention group. b Patients with other evidence of atherosclerosis or other manifestation of vascular disease at enrolment. ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; SE, standard error.
Figure 3 Mean low-density lipoprotein cholesterol levels in patients with stabilized lipid-lowering therapy. n , the number of patients in the category on stabilized lipid-lowering therapy and with non-missing low-density lipoprotein cholesterol goal data. a Primary prevention: at low-density lipoprotein cholesterol measurement, 142 patients enrolled as secondary prevention, whose first atherosclerotic cardiovascular disease event occurred after the date low-density lipoprotein cholesterol levels were stabilized, are included in the primary prevention group. b Patients with other evidence of atherosclerosis or other manifestation of vascular disease at enrolment. ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; SE, standard error.CC-BY-NC · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 963

Metadata

Authors
Ray, K. K., Molemans, B., Schoonen, W. M., Giovas, P., Bray, S., Kiru, G., Murphy, J., Banach, M., De Servi, S., Gaita, D., Gouni-Berthold, I., Hovingh, G. K., Jozwiak, J. J., Jukema, J. W., Kiss, R. G., Kownator, S., Iversen, H. K., Maher, V., Masana, L., Parkhomenko, A., Peeters, A., Clifford, P., Raslova, K., Siostrzonek, P., Romeo, S., Tousoulis, D., Vlachopoulos, C., Vrablik, M., Catapano, A. L., Poulter, N. R., & study, T. D. V.
Affiliations
  • Imperial College London (GB)
  • Amgen (United States) (US)
  • Amgen (United Kingdom) (GB)
  • Amgen Hellas, 4 Gravias Street, Maroussi, 15125, Athens, Greece
  • Medical University of Lodz (PL)
  • IRCCS MultiMedica, Via Milanese, 300, 20099 Sesto San Giovanni, Milan, Italy
  • Institutul de Boli Cardiovasculare, Fundatia Cardioprevent, Universitatea de Medicina si Farmacie Victor Babes din Timisoara, Timişoara 300041, Romania
  • Polyclinic for Endocrinology, Diabetes and Preventive Medicine, Kerpener Str. 62, 50937 Cologne, Germany
  • University of Amsterdam (NL)
  • University of Opole (PL)
  • Leiden University Medical Center (NL)
  • Hungarian Army Medical Center, Budapest, 1134, Hungary
  • Centre Cardiologique et Vasculaire, 36 Route de la Briquerie, 57100, Thionville, France
  • University of Copenhagen (DK)
  • Trinity College Dublin (IE)
  • Institut de Recerca Biomèdica Catalunya Sud (ES)
  • Emergency Cardiology Department, Institute of Cardiology, Kiev, Ukraine
  • Cliniques Universitaires Saint Luc, Avenue Hippocrate 10, 1200, Brussels, Belgium
  • Hammersmith Hospital (GB)
  • Slovak Medical University, 831 01 Bratislava, Slovakia
  • Ordensklinikum Linz Barmherzige Schwestern (AT)
  • Sahlgrenska University Hospital (SE)
  • National and Kapodistrian University of Athens (GR)
  • Charles University, Prague, 116 36 Czech Republic
  • MultiMedica (IT)
Corresponding author
Ray, Kausik K
Venue
European Journal of Preventive Cardiology
Published
2020-08-28
Volume
28
Issue
11
Pages
1279-1289
ISSN
  • 2047-4873 (ISSN-L)
  • 2047-4881
OpenAlex
W3120916025
Cited by
839
References
10
Citations by year
2026: 137 · 2025: 162 · 2024: 143 · 2023: 165 · 2022: 139 · 2021: 79 · 2020: 12
FWCI
90.18
Type
journal article
Language
en
Open access
Locations
  • European Journal of Preventive Cardiology (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
  • Leiden Repository (Leiden University) (submittedVersion, cc-by-nc)
  • Rovira & Virgili repository (submittedVersion, cc-by)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc)
  • DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
  • Pure Amsterdam UMC (submittedVersion, cc-by)
  • Spiral (Imperial College London) (submittedVersion, cc-by-nc)
Funders
Amgen (Europe) GmbH
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
lipid-lowering therapy, LDL cholesterol goal attainment, statins, ezetimibe, PCSK9 inhibitors, guideline implementation, primary prevention, secondary prevention, very high-risk patients, non-statin therapy, cardiovascular risk management, ESC/EAS guidelines
MeSH terms
Proprotein Convertase 9, Anticholesteremic Agents, Cardiovascular Diseases, Cross-Sectional Studies, Humans, Cholesterol, LDL, Primary Health Care, Risk Factors, Biomarkers, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: EU-Wi d e Cross-Section a l Obser v at i o n al Study of Lipid-Modifying Therapy Use in Se c ondary and Pr i mary Care: the DA VINCI study. https://app.cochat.ai/papers/10.1093/eurjpc/zwaa047
The paper
Ray, K. K., Molemans, B., Schoonen, W. M., Giovas, P., Bray, S., Kiru, G., Murphy, J., Banach, M., De Servi, S., Gaita, D., Gouni-Berthold, I., Hovingh, G. K., Jozwiak, J. J., Jukema, J. W., Kiss, R. G., Kownator, S., Iversen, H. K., Maher, V., Masana, L., . . . study, T. D. V. (2021). EU-Wi d e Cross-Section a l Obser v at i o n al Study of Lipid-Modifying Therapy Use in Se c ondary and Pr i mary Care: the DA VINCI study. European Journal of Preventive Cardiology. https://doi.org/10.1093/eurjpc/zwaa047

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.